Search PubMed⌕ Search

PubMed · 2442113

Future developments in interferon therapy.

Abstract

The antitumour effects of interferons in animals and humans are well known. Despite the fact, however, that the 3 types of human interferon, leukocyte alpha-interferon, fibroblast beta-interferon and immune gamma-interferon are available in large amounts through recombinant DNA technology, the practical applicability of interferon therapy in cancer is still not clear. An initial approach to this problem is to determine the mechanism of action of interferons and to find out why, in certain circumstances, they are inactive. There are various ways in which interferon may control tumours--i.e. antiviral action, inhibition of cell growth, stimulation of cell differentiation, changes in cells modulating the susceptibility to immune rejection, or effects on the host immune systems (natural killer system and cytotoxic proteins). The implications of these data in the use of interferon in cancer therapy need to be evaluated. Both alpha- and beta-interferons may have beneficial effects on growth inhibition and differentiation, but gamma-interferon is probably more effective in boosting the immune recognition and rejection of tumour cells. A combination of alpha- and gamma-interferon may give the best results in vivo, since they often act synergistically in vitro. The sensitivity of individual tumour cells to the various types of interferon needs to be evaluated by measurement of oncogenes mRNA inhibition, G0/G1 arrest and increase in various H-La antigens. Finally, the aim of any treatment (antiviral action, tumour regression, prevention of metastasis, decreased tumour growth and increased cell differentiation) should be an important consideration in whether interferon therapy is chosen. A major problem remains in understanding why only a small proportion of patients usually show an objective response to interferon.(ABSTRACT TRUNCATED AT 250 WORDS)

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Boiron. 1987. Future developments in interferon therapy.. https://doi.org/10.1002/ijc.2910390709. https://searchpubmed.org/record/pubmed%3A2442113/future-developments-in-interferon-therapy

Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite Search PubMed by Indiciae: BibTeX · RIS.

KEEP EXPLORING

Related citations

[Fibromyalgia. Diagnostics--disease approach--therapy].

Fibromyalgia is a complex of symptoms predominantly affecting females and consisting of widespread pain. Etiology and pathogenesis are not sufficiently known yet, however, there is the assumption that fibromyalgia is looked at as being an illness with biological, psychological, and social aspects. Therefore, the treatment of fibromyalgia calls for a multimodal therapy approach. The importance of fibromyalgia has been recognized within the German health system by creating the new ICD code M79.70 and by assigning fibromyalgia its own rheumatologic DRG (I79Z). In future research of fibromyalgia special attention needs to be placed upon gender-specific problems.

Combined Modality Therapy↗

Lack of survival benefit of post-operative radiation therapy in prostate cancer patients with positive lymph nodes.

Randomized data from SWOG 8794 and EORTC 22911 confirm the benefit of post-operative radiation therapy (RT) for selected patients with pT3 prostate cancer (CaP) after radical prostatectomy (RP). However, data regarding the potential benefit of RT for patients post-RP with positive lymph node (+LN) involvement are limited. We analyzed the Surveillance Epidemiology End Results (SEER) registry for population-based data on efficacy of post-operative RT for +LN patients after RP. As LN data have only been captured by SEER since 1988, we analyzed data for 1988-1992, with specific attention to 10-year relative survival (defined as observed survival divided by the survival of a gender-, age- and race-matched population cohort without disease). Specifically analyzed were data for 1921 patients with nonmetastatic prostate cancer who underwent surgery alone, or surgery followed by RT, and who had +LNs documented. SEER does not code the interval between surgery and RT, so the ratio of patients receiving salvage versus adjuvant therapy is unknown. Using follow-up data through 2002, post-diagnosis survival was examined by number of +LNs. There was no significant relative survival benefit for +LN patients receiving post-operative RT (chi(2)P=0.270). These data do not support routine use of post-operative RT for patients with +LNs in the surgical specimen.

Combined Modality Therapy↗